The Latest Breaking News from FDA

SACRAMENTO, Calif. — Scientists, doctors and pathologists are questioning the Sacramento County coroner’s conclusion that Lori McClintock’s death was related to white mulberry, a plant that has been used as an herbal remedy for centuries — and one that the coroner’s botanical consultant called “not toxic” in a letter to…

In recent months, the psychedelics space has been ground for increasing collaborations. In some cases it was to advance scientific studies.

The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON’s (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares…

The U.S. Food and Drug Administration has issued a Class I recall, the agency's most serious category, for certain tracheal tubes made by Medtronic.

While the country awaits federal approval of a new ALS drug, people in South Florida with the disease already are using it.

The omicron-specific booster vaccine hit the market — some wonder if it's worth getting

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz. Just days after the FDA’s move, the Centers for Disease Control and Prevention followed, recommending updated boosters for anyone age 12 and up who had received at least two doses of the original COVID-19…

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.

Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares…

Rising prevalence of chronic diseases and the increasing aging population are significant growth drivers of the healthcare industry. Moreover, growing investments in technological advancements should bode well for the industry. Thus, we think investing in quality healthcare stocks Johnson & Johnson (JNJ), Pfizer (PFE), Novo Nordisk (NVO), Bristol-Myers Squibb (BMY),…

"There is no single magic bullet to solving all problems with access and affordability issues."